Article Text

Download PDFPDF
Frequent Loss of Tumor Suppressor ARID1A Protein Expression in Adenocarcinomas/Adenosquamous Carcinomas of the Uterine Cervix
  1. Atsuko Katagiri, MD*,
  2. Kentaro Nakayama, MD, PhD*,
  3. Mohammed Tanjimur Rahman, MBBS*,
  4. Munmun Rahman, MBBS*,
  5. Hiroshi Katagiri, MD*,
  6. Masako Ishikawa, MD, PhD*,
  7. Tomoka Ishibashi, MD*,
  8. Kouji Iida, BSc*,
  9. Yoshiro Otsuki, MD,
  10. Satoru Nakayama, MD and
  11. Kohji Miyazaki, MD, PhD*
  1. *Department of Obstetrics and Gynecology, Shimane University School of Medicine, Shimane; Departments of
  2. Pathology, and
  3. Obstetrics and Gynecology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
  1. Address correspondence and reprint requests to Kentaro Nakayama, MD, PhD, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane, Japan 6938501. E-mail: kn88@med.shimane-u.ac.jp.

Abstract

Objectives Expression of ARID1A (the adenine, thymine-rich interactive domain 1A), a putative tumor suppressor, has recently been shown to be lost in several tumor types. This study investigated whether ARID1A expression was also lost in cervical squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas.

Methods A total of 91 patients with cervical carcinoma were enrolled. Cervical carcinoma specimens were examined for ARID1A protein expression by immunohistochemistry. The correlations between the loss of ARID1A expression and clinicopathological characteristics, and prognosis were investigated.

Results Using immunohistochemistry, the frequency of loss of ARID1A expression in adenocarcinomas/adenosquamous carcinomas (31.1% [14/45]) was significantly higher than that in squamous cell carcinomas (6.5% [3/46]; P = 0.0017). There was no significant association between the loss of ARID1A expression and International Federation of Gynecology and Obstetrics staging, lymphovascular space invasion, lymph node metastasis, age, and Ki-67 LI in cervical adenocarcinomas/adenosquamous carcinomas. Loss of ARID1A expression was not correlated with shorter overall/disease-free survival in cervical adenocarcinomas/adenosquamous carcinomas.

Conclusions In conclusion, this study provides the first evidence of the frequent loss of ARID1A protein expression in cervical adenocarcinomas/adenosquamous carcinomas. No significant differences between ARID1A positive and negative cases were observed with respect to any clinicopathological features examined.

  • ARID1A
  • Tumor suppressor gene
  • Cervical carcinomas
  • Squamous cell carcinomas
  • Adenocarcinoma/adenosquamous carcinomas

Statistics from Altmetric.com

Footnotes

  • This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan and the Kanae Research Foundation.

  • The authors declare that there are no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.